Form 8-K - Current report:
SEC Accession No. 0001193125-25-141755
Filing Date
2025-06-17
Accepted
2025-06-17 07:30:35
Documents
14
Period of Report
2025-06-11
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d32789d8k.htm   iXBRL 8-K 53548
2 EX-3.1 d32789dex31.htm EX-3.1 21944
3 EX-3.2 d32789dex32.htm EX-3.2 147462
  Complete submission text file 0001193125-25-141755.txt   383810

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA dvax-20250611.xsd EX-101.SCH 2851
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE dvax-20250611_lab.xml EX-101.LAB 18740
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dvax-20250611_pre.xml EX-101.PRE 11708
17 EXTRACTED XBRL INSTANCE DOCUMENT d32789d8k_htm.xml XML 3872
Mailing Address 2100 POWELL STREET SUITE 720 EMERYVILLE CA 94608
Business Address 2100 POWELL STREET SUITE 720 EMERYVILLE CA 94608 5108485100
DYNAVAX TECHNOLOGIES CORP (Filer) CIK: 0001029142 (see all company filings)

EIN.: 330728374 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34207 | Film No.: 251051826
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)